1Nina M, Bella K, Etty I, et al. Sensitization to Insulin Induced by β. β′ - methyl - Substituted Hexadecanedioic Acid(MEDICA16) in Obese Zucker Rats in Vivo. Diabetes 1997,46:1958.
2Ueda H, Kegami H, Kawagnchiy et al. Inhertance of Diabetes in a New Mouse Model of NIDDM, the NSY Mouse. Diabetologia 1997, 40: 671.
3George A, Angela MB, Steven MW, et al. Effects of Mutation in the Human Uncoupling Protein 3 Gene on the Respirator Quotient and Fat Oxidation in Severe Obesity and Type 2 Diabetes. J Clin Invest 1998, 102(7) :1345.
4Gokgam SH, Peter A, Jose F, et al. Increased Adipose Tissue Expression of Tumor Necrosis Factor - α in Human Obesity and Insulin Resistance. J Clin Invest 1995, 95:2409.
5Dominic JW, Jolio SG, Heather T, et al. Disruption of IRS- 2 Causese Type 2 Diabetes in Mice. Nature 1998, 391 (26):900.
6Belfiore F, Iannello S, Volpicelli G. Insulin sensitivity indices calculated from basal and OGTT - induced insulin, glucose,and FFA level. Mol Genet Metab 1998, 63:134.
7Oakes ND, Camilleri SC, Furler SM et al. The insulin sensitizer, BRL49653, reduces systemic fatty acid supply and utilization and tissue lipid availability in the rat. Metabolism 1997, 46:935.
8Tang Y, Osawa H, Onuma H et al. Improvement in insulin resistance and the restoration of reduced phosphodiesterase 3B gene expression by pioglitazone in adipose tissue of obese diabetic KKAy mice. Diabetes 1999, 48: 1830.
9Brown KK, Henke BR, Blancbard SG et al,. A novel N -aryl tyrosine activator of peroxisome proliferator - activated receptor - γ revesses the diabetic phenotype of the Zucker diabetic fatty rat. Diabetes 1999, 48:1415.
10Gregorio F, Ambrosi F, Manfrini S et al. Metformin, plasma glucose and free fatty acids in type Ⅱ diabtic out - patients:results of a clinical study. Diabetes Res Clin Pract 1997, 37 : 21.
5[7]Bo S, Cavallo - Perin P, Gentile L, et al. Low HDL-cholesterol: a component of the metabolic syndrome only in the presence of fasting hypertriglyceriidemia n type 2 diabetic patients. Diabetes Metab 2001 ;27(1): 31 - 35.
6[8]Boden G. Role of fatty aids in the pathogenesis of insulin resistance and NIDDM. Diabetes 1997 ;46: 3 - 10.
7[9]Laakso M, Lehto S, Penttila I, et al. Lipids and liporoteins predicting coronary heart disease mortality and morbidity in patients with non - insulin dependent diabetes. Circulation 1993;1421 - 1430.
8[10]Lamarche B, Tchernof A, Manrige P, et al. Fasting insulin and apolipo protein B levels and low - density lipoprotein particle size as risk factors for ischemic heart disease.JAMA 1998 ;279:1955 - 1961.
9[11]Pyorala K, Pederson TR, Kjekshus J, et al. For the Scandinavian Simvastatin Surviral Study: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Slmvastation Survival Study(4S), Diabetes Care 1997;20:614 - 620.
10[12]Grover SA, Coupal L, Zowall H, Dorais. Cost - effectiveness of treating hyperlipidemia in the presence of diabetes: who should be treated? Circulation 2000; 102(7):722 - 727.